News Focus
News Focus
Followers 1
Posts 153
Boards Moderated 0
Alias Born 06/04/2019

Re: Maple tree post# 4370

Monday, 11/29/2021 3:03:50 PM

Monday, November 29, 2021 3:03:50 PM

Post# of 20607
I appreciate the remarks from GC but I tend to look at the data.
I had to go back to find what drove me to dive into the 2005 patent landscape. Here is the link:

https://www.tcellprotect.com/about-the-product/

"Shikonin is known for its anti-viral, anti-microbial and anti-cancer properties, while clinical trials on its anti-cancer properties continues to be performed. In fact, there is a patent established in 2005 on the anti-viral properties of Shikonin. A test performed during the SARS epidemic showed that Shikonin reduced the course of SARS from 11 to 6 days and that it has anti-viral significant properties. Dr. Dorit Arad's team at eXegenics in 2001 found that Shikonin has molecular activity against several viruses, particularly the 3C-target viral protease enzyme, and it was detected as the most active compound among the 300,000 compounds studied in this study. Gromwell Root, which contains 30% Shikonin, is regulated in Israel as a safe herbal supplement with a therapeutic index> 100 for concentrations up to 20mg per Kg."

The clinical results on SARS were positive and I expect the C19 results to be similar. GC probably wants to avoid opening a can of worms. It is a supplement but the scientist are obviously convinced that it has anti-viral properties, eh? Kudos for this presentation by the way. It is excellent and hits the nail on the head. I have sent it to friends and family.
Volume:
Day Range:
Bid:
Ask:
Last Trade Time:
Total Trades:
  • 1D
  • 1M
  • 3M
  • 6M
  • 1Y
  • 5Y